Experimental study on dynamic regulation of acetylcholine in striatum of rat parkinson disease model and behavior observation

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 32, Issue 5, 2012, Pages 732-736

  Cao, Fei ^a   Luo, Fang ^b   Chen, Li ^a   Chen, Han ^a   Wei, Guirong ^a   Cai, Junjie ^a   Xu, Hui ^a   Tong, Etang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Hubei Xinhua Hospital   (China)

Author keywords

Acetylcholine; Dopamine; Parkinson's disease

Indexed keywords

ACETYLCHOLINE;

ANIMAL; ARTICLE; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; MALE; METABOLISM; PARKINSON DISEASE; PATHOLOGY; RAT; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; MALE; PARKINSON DISEASE; RATS; RATS, WISTAR;

EID: 84870489540     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-012-1026-2     Document Type: Article

References (15)

1. Chapman MA. Does smoking reduce the risk of Parkinson's disease throu gh stimulation of the ubiquitin- proteasome system? Med Hypotheses, 2009, 73(6): 887-891
2. Bohnen NI, Albin RL. Cholinergic denervation occurs early in Parkinson disease. Neurology, 2009, 73(4): 256-257
3. Veena J, Rao BS, Srikumar BN. Regulation of adult neurogenesis in the hippocampus by stress, acetylcholine and dopamine. J Nat Sci Biol Med, 2011, 2(1):26-37
4. Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord, 2011, 26(14):2496-2503
5. Bao XM, Shu SY. A stereotaxic atlas of the rat brain. Beijing: The People ' s Medical Publishing House, 1991, 1-2
6. Lacroix LP, Ceorlin L, Zocchi A. Selective dopamine D (3) receptor antagonists enhance cortic al acetylcholine levels measured with high-performance liquid chromatography/ tandem mass spectrometry without anti-cholin esterases. J Neurosci Methods, 2006, 157(1): 25-31 (Pubitemid 44287068)
7. Tian Q, Lin ZQ, Wang XC, et al. Injection of okadaic acid into the meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit. Neuroscience, 2006, 126(2):277-284 (Pubitemid 38780803)
8. Arruda Paes PC, de Magalhaes L, Camillo MA, et al. Ionotropic glutamate receptors regulating labeled acetylcholine release from rat striatal tissue in vitro: possible involvement of receptor modulation in magnesium sensitivity. Neurosci Res, 2004, 49(3):289-295 (Pubitemid 38757936)
9. Xiang Z, Thompson AD, Jones CK, et al. Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease. J Pharmacol Exp Ther, 2012, 340(3):595-603
10. Russo P, Taly A. α7-nicotinic acetylcholine receptors: An old actor for new different roles. Curr Drug Targets, 2012, 13(5):574-578
11. Huang X, Cheng Z, Su Q, et al. Neuroprotection by nicotine against colchicine-induced apoptosis is mediated by PI3-kinase-Akt pathways. Int J Neurosci, 2012, 122(6): 324-332
12. Yu W, Mechawar N, Krantic S, et al. α7 Nicotinic receptor activation reduces β-amyloid-induced apoptosis by inhibiting caspase-independent death through phosphatidylinositol 3-kinase signaling. J Neurochem, 2011, 119(4): 848-858
13. Quarta D, Ciruela F, Patkar K. Heteromeric nicotinic acetylcholine- dopaminecomplexes modulate striatal dopamine release. Neuropsychopharmacology, 2006, 170(1): 148-155
14. Rode F, Munro G, Holst D, et al. Positive allosteric modulation of α4β2 nAChR agonist induced behaviour. Brain Res, 2012, 1458:67-75
15. Quik M, Wonnacott S. α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev, 2011, 63(4):938-966